In a research report published Monday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT)with a price target of $22.
Roth Capital analyst Debjit Chattopadhyay maintained Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price target, as the company initiated dosing in a clinical study of …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $22, which represents a potential …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price target, which represents a potential upside of …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a $22 price …
In a research report issued today, William Blair analyst Tim Lugo assigned an Outperform rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a price …
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $45 price target, as longer …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target, as …
